
3 Pharmaceuticals Company, Shopping Malls Owner and Dairy Products Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy
Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy: ROE of 11.1% to 15.9% and FY22 to FY26 revenue CAGR of 8.4% to 31.0%. Prices as of 17 Nov 2026.
Updated: 18 Nov 2026 • 3:45 pm
Posted by:

Quick Answer
The three tablet maker, shopping mall and milk stocks to watch are Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy. Their return on equity ranges from 11.1% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 31.0%. Dodla Dairy has the highest return on equity at 15.9%, while Phoenix Mills has the fastest revenue growth at 31.0% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Tablet maker, shopping mall and milk stocks let investors follow companies that serve a growing part of the Indian economy. Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy cover a pharmaceuticals company, a shopping malls owner and a dairy products company.
This list covers three tablet maker, shopping mall and milk stocks with complete current figures: Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Tablet Maker, Shopping Mall and Milk Stocks?
Tablet maker, shopping mall and milk stocks are listed companies that make branded and generic medicines for India and global markets, own and run large shopping malls and offices, and collect and sell milk, curd and ghee. Their earnings depend on medicine demand, mall footfall and dairy demand.
Tablet Maker, Shopping Mall and Milk Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 1,050.65 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Phoenix Mills | 2,229 | 68,308 | 41.9 | 30.7 | 11.1 | 0.48 |
| Dodla Dairy | 977.8 | 6,064 | 24.8 | 33.9 | 15.9 | 0.03 |
On valuation, Alembic Pharmaceuticals and Dodla Dairy trade at a P/E below the industry P/E, while Phoenix Mills trades above it, which reflects the growth the market already expects. Readers comparing tablet maker, shopping mall and milk stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in tablet maker, shopping mall and milk stocks can use the coming numbers to test whether growth is holding.
Why Do Tablet Maker, Shopping Mall and Milk Stocks Have a Strong Roadmap in India?
Tablet maker, shopping mall and milk stocks have a strong roadmap in India because steady demand for medicines, growing footfall in malls and rising demand for packaged dairy keep widening the market for these companies.
- Pharmaceuticals. Doctors prescribe trusted brands.
- Malls. Shoppers return to large retail centres.
- Dairy. Households buy milk and curd every day.
Why Alembic Pharmaceuticals Features Among These Tablet Maker, Shopping Mall and Milk Stocks
Among the tablet maker, shopping mall and milk stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Phoenix Mills Features Among These Tablet Maker, Shopping Mall and Milk Stocks
Among the pharma brand, retail property and dairy shares on this list, Phoenix Mills owns and operates premium retail malls in major cities under the Phoenix brand and also has commercial, residential and hospitality assets.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 68,308 crore. The stock trades at a P/E of 41.9, above the industry P/E of 30.7.
Revenue rose from Rs 1,558 crore in FY22 to Rs 4,594 crore in FY26, a compound annual growth rate of 31.0%. Net profit grew from Rs 248 crore in FY22 to Rs 1,557 crore in FY26, which works out to a compound annual growth rate of 58.3%. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit rose 23.0% to Rs 394 crore.
Roadmap: The company is adding mall space and commercial assets as consumer spending rises. Rental income linked to footfall and consumption supports earnings as the portfolio matures.
What to watch: Track consumption in its malls, new mall openings and rental growth.
Why Dodla Dairy Features Among These Tablet Maker, Shopping Mall and Milk Stocks
Among the three companies on this list, Dodla Dairy, based in Hyderabad, procures milk from farmers and sells milk and value-added products such as curd, ghee and ice creams across South and East India, with operations in Africa.
Revenue rose from Rs 2,257 crore in FY22 to Rs 4,186 crore in FY26, a compound annual growth rate of 16.7%. Net profit grew from Rs 133 crore in FY22 to Rs 267 crore in FY26, which works out to a compound annual growth rate of 19.1%.
In the June 2026 quarter, revenue grew 18.3% year on year to Rs 1,212 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,064 crore. The stock trades at a P/E of 24.8, below the industry P/E of 33.9.
Roadmap: The company is growing its value-added products, widening its geographic coverage and adding procurement strength. Value-added dairy brings better margins than plain milk, and a bigger farmer base secures supply.
What to watch: Track milk procurement prices and the growth in value-added products.
Alembic Pharmaceuticals vs Phoenix Mills vs Dodla Dairy on Key Financials
The table below sets the three tablet maker, shopping mall and milk stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Phoenix Mills | 1,558 | 4,594 | 31.0% | 1,557 | 33.9% |
| Dodla Dairy | 2,257 | 4,186 | 16.7% | 267 | 6.4% |
Dodla Dairy posts the highest return on equity in this group at 15.9%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Phoenix Mills shows the fastest revenue growth with a 31.0% compound annual rate. A useful habit with tablet maker, shopping mall and milk stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Phoenix Mills | 985 | 1,115 | 13.3% |
| Dodla Dairy | 1,024 | 1,212 | 18.3% |
Key Risks to Check Before Investing in Tablet Maker, Shopping Mall and Milk Stocks
Every theme carries risks that deserve a check before any decision. For these tablet maker, shopping mall and milk stocks, the main points are: Long-term pharma brand, retail property and dairy shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
- Raw material costs. Ingredient and packaging prices can move margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter tablet maker, shopping mall and milk stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Tablet Maker, Shopping Mall and Milk Stocks
Tablet maker, shopping mall and milk stocks reward investors who follow demand trends, order books and margins together. Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy each have a clear plan to grow. Based on the 17 November 2026 close, Alembic Pharmaceuticals trades at Rs 1,050.65, Phoenix Mills at Rs 2,229 and Dodla Dairy at Rs 977.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these tablet maker, shopping mall and milk stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track tablet maker, shopping mall and milk stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are tablet maker, shopping mall and milk stocks?
Ans. Tablet maker, shopping mall and milk stocks are listed companies that make branded and generic medicines for India and global markets, own and run large shopping malls and offices, and collect and sell milk, curd and ghee. Their earnings depend on medicine demand, mall footfall and dairy demand. This list looks at three of them, Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which tablet maker, shopping mall and milk stocks are covered in this list?
Ans. This list covers Alembic Pharmaceuticals, Phoenix Mills and Dodla Dairy. Based on the 17 November 2026 close, Alembic Pharmaceuticals traded at Rs 1,050.65, Phoenix Mills at Rs 2,229 and Dodla Dairy at Rs 977.8. Their return on equity ranges from 11.1% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 31.0%.
Why do tablet maker, shopping mall and milk stocks have a strong future roadmap in India?
Ans. Tablet maker, shopping mall and milk stocks have a strong roadmap in India because steady demand for medicines, growing footfall in malls and rising demand for packaged dairy keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Doctors prescribe trusted brands. Malls. Shoppers return to large retail centres. Dairy. Households buy milk and curd every day. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Phoenix Mills performed financially?
Ans. Revenue rose from Rs 1,558 crore in FY22 to Rs 4,594 crore in FY26, a compound annual growth rate of 31.0%. Net profit grew from Rs 248 crore in FY22 to Rs 1,557 crore in FY26, which works out to a compound annual growth rate of 58.3%. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit rose 23.0% to Rs 394 crore. The company has a return on equity of 11.1%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 68,308 crore. The stock trades at a P/E of 41.9, above the industry P/E of 30.7. Looking ahead, the company is adding mall space and commercial assets as consumer spending rises. Rental income linked to footfall and consumption supports earnings as the portfolio matures.
How has Dodla Dairy performed financially?
Ans. Revenue rose from Rs 2,257 crore in FY22 to Rs 4,186 crore in FY26, a compound annual growth rate of 16.7%. Net profit grew from Rs 133 crore in FY22 to Rs 267 crore in FY26, which works out to a compound annual growth rate of 19.1%. In the June 2026 quarter, revenue grew 18.3% year on year to Rs 1,212 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,064 crore. The stock trades at a P/E of 24.8, below the industry P/E of 33.9. Looking ahead, the company is growing its value-added products, widening its geographic coverage and adding procurement strength. Value-added dairy brings better margins than plain milk, and a bigger farmer base secures supply.
What risks should investors check before buying tablet maker, shopping mall and milk stocks?
Ans. Investors should check a few risks before buying tablet maker, shopping mall and milk stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Consumer spending. Sales follow festivals, incomes and consumer mood. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of tablet maker, shopping mall and milk stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





